Analyst firms · H.C. Wainwright · REGN

H.C. Wainwright REGN price target and rating history

Regeneron Pharmaceuticals Inc. (REGN) · Health Care

H.C. Wainwright rates Regeneron Pharmaceuticals Inc. (REGN) Buy with a $844 price target, as of its latest action on Nov 5, 2021. It has published 5 rating actions on REGN since June 2021, including 0 upgrades and 0 downgrades. Across 9 firms with a REGN price target in the last 12 months, the median target is $798.

Current rating
Buy
Price target
$844
Median target, all firms
$798
Actions on REGN
5

H.C. Wainwright price target on REGN

$844$774$70320222023202420252026
H.C. Wainwright price target on REGN, each point a stated target, June 2021 to November 2021.

Every H.C. Wainwright rating on REGN

How other firms rate REGN

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$850Oct 1, 2026
CitigroupNeutral$700May 18, 2026
Leerink PartnersMarket Perform$641May 18, 2026
Piper SandlerOverweight$875Mar 31, 2026
BarclaysOverweight$923Mar 6, 2026
BofA SecuritiesBuy$860Jan 7, 2026
Morgan StanleyEqual-Weight$767Dec 3, 2025
Truist SecuritiesBuy$798Nov 24, 2025
HSBCBuy$255Nov 24, 2025

Questions about H.C. Wainwright and REGN

What is H.C. Wainwright's price target for REGN?
H.C. Wainwright's latest stated price target for Regeneron Pharmaceuticals Inc. (REGN) is $844, from its action on Nov 5, 2021.
What is H.C. Wainwright's rating on REGN?
H.C. Wainwright rates REGN Buy, a bullish rating, as of Nov 5, 2021.
When did H.C. Wainwright last change its view on REGN?
On Nov 5, 2021, H.C. Wainwright raises its price target to $844 from $842, keeps Buy.
How does H.C. Wainwright's REGN target compare with other analysts?
Across 9 firms with a REGN price target in the last 12 months, the median target is $798.

More REGN rating histories

All H.C. Wainwright ratingsREGN news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.